A landmark event in the history of antimalarial drug research
For the past 7 years, MMV has partnered with GSK on a number of highly innovative antimalarial projects that include a pipeline of development candidates as well as a new drug for radical cure of P. vivax. We have also collaborated to screen more than 2 million compounds from GSK’s library for antimalarial activity. These findings will be made available in the public domain.
“This is a landmark event in the history of antimalarial drug research,” said Dr Chris Hentschel, President and CEO of MMV. “We look forward to the inclusion into our portfolio of promising compounds from this screening.”